{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T08:42:20Z","timestamp":1783759340712,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Future Healthcare Journal"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.fhj.2025.100485","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:49:12Z","timestamp":1765810152000},"page":"100485","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rheumatology 2050: How our specialty is changing"],"prefix":"10.1016","volume":"12","author":[{"given":"Mariam","family":"Omar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Bechman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James","family":"Galloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9194","key":"10.1016\/j.fhj.2025.100485_bib0001","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"issue":"10055","key":"10.1016\/j.fhj.2025.100485_bib0002","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.fhj.2025.100485_bib0003","first-page":"e427","article-title":"Stratification of biologic therapy in rheumatoid arthritis by synovial pathology: results of the phase 3b STRAP randomised trial","volume":"5","author":"Humby","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"Suppl 4","key":"10.1016\/j.fhj.2025.100485_bib0004","doi-asserted-by":"crossref","first-page":"iv28","DOI":"10.1093\/rheumatology\/keab617","article-title":"IL-23 and axial disease: do they come together?","volume":"60","author":"Mease","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.fhj.2025.100485_bib0005","first-page":"1045","article-title":"The effect of B-cell depletion on seropositive and seronegative rheumatoid arthritis: clinical outcomes and immunologic mechanisms","volume":"59","author":"Cambridge","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"9842","key":"10.1016\/j.fhj.2025.100485_bib0006","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(12)61079-4","article-title":"Interstitial lung disease in connective tissue disorders","volume":"380","author":"Fischer","year":"2012","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.fhj.2025.100485_bib0007","first-page":"e843","article-title":"Mechanisms of progressive fibrosis in connective tissue disease-associated interstitial lung disease","volume":"3","author":"Spagnolo","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.fhj.2025.100485_bib0008","first-page":"1","article-title":"Clinical features in VEXAS syndrome: a systematic review","volume":"00","author":"Al-Hakim","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"27","key":"10.1016\/j.fhj.2025.100485_bib0009","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.fhj.2025.100485_bib0010","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10423","key":"10.1016\/j.fhj.2025.100485_bib0011","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"},{"issue":"10423","key":"10.1016\/j.fhj.2025.100485_bib0012","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S0140-6736(23)02650-8","article-title":"Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial","volume":"403","author":"Rech","year":"2024","journal-title":"Lancet"},{"issue":"10423","key":"10.1016\/j.fhj.2025.100485_bib0013","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(24)00055-2","article-title":"Abatacept in individuals with autoantibody-positive arthralgia at risk for rheumatoid arthritis","volume":"403","author":"van der Helm-van Mil","year":"2024","journal-title":"Lancet"},{"issue":"10346","key":"10.1016\/j.fhj.2025.100485_bib0014","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(22)01193-X","article-title":"Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"400","author":"Krijbolder","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.fhj.2025.100485_bib0015","article-title":"A randomised, placebo-controlled trial of hydroxychloroquine in incomplete lupus","author":"Olsen","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.fhj.2025.100485_bib0016","article-title":"A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis","author":"Deane","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.fhj.2025.100485_bib0017","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"Anti-CD19 CAR T-cell therapy for autoimmune diseases","volume":"390","author":"Mackensen","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.fhj.2025.100485_bib0018","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-targeting CAR T-cell therapy for myositis and interstitial lung disease associated with Antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.fhj.2025.100485_bib0019","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.fhj.2025.100485_bib0020","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.fhj.2025.100485_bib0021","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40164-025-00633-8","article-title":"The clinical landscape of CAR NK cells","volume":"14","author":"J\u00f8rgensen","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.fhj.2025.100485_bib0022","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","article-title":"Bispecific T cell engager therapy for refractory rheumatoid arthritis","volume":"30","author":"Bucci","year":"2024","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.fhj.2025.100485_bib0023","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.fhj.2025.100485_bib0024","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.fhj.2025.100485_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"issue":"4","key":"10.1016\/j.fhj.2025.100485_bib0026","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.fhj.2025.100485_bib0027","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/annrheumdis-2020-217139","article-title":"EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors","volume":"80","author":"Kostine","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.fhj.2025.100485_bib0028","first-page":"85","article-title":"Immune checkpoint inhibitor-associated autoimmune syndromes: understanding the spectrum and identifying risk factors","volume":"20","author":"Cappelli","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.fhj.2025.100485_bib0029","first-page":"871","article-title":"Pre-existing autoantibodies and the development of immune-related adverse events in patients treated with immune checkpoint inhibitors","volume":"82","author":"Wang","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.fhj.2025.100485_bib0030","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/ije\/dyaa287","article-title":"Occupational exposure to respirable crystalline silica and risk of autoimmune rheumatic diseases: a nationwide cohort study","volume":"50","author":"Boudigaard","year":"2021","journal-title":"Int J Epidemiol"},{"issue":"4","key":"10.1016\/j.fhj.2025.100485_bib0031","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1136\/ard.2004.022053","article-title":"Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study","volume":"64","author":"Stolt","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.fhj.2025.100485_bib0032","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002055","article-title":"Association between long-term exposure to air pollution and immune-mediated diseases: a population-based cohort study","volume":"8","author":"Adami","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.fhj.2025.100485_bib0033","article-title":"Interplay between endocrine disruptors and immunity: a narrative review","volume":"12","author":"Vetrano","year":"2021","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.fhj.2025.100485_bib0034","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.autrev.2014.07.001","article-title":"Obesity in autoimmune diseases: not a passive bystander","volume":"13","author":"Versini","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"10395","key":"10.1016\/j.fhj.2025.100485_bib0035","first-page":"452","article-title":"Semaglutide in patients with overweight or obesity and knee osteoarthritis: the STEP 9 trial","volume":"403","author":"Messier","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.fhj.2025.100485_bib0036","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mechanisms underlying cardiometabolic and anti-inflammatory effects of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"issue":"Suppl 2","key":"10.1016\/j.fhj.2025.100485_bib0037","first-page":"ii18","article-title":"Ethnic disparities in access to biologic therapies in England: a national analysis of prescribing data","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology (Oxford)"},{"issue":"24","key":"10.1016\/j.fhj.2025.100485_bib0038","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1056\/NEJMsb2503956","article-title":"Generative AI in medicine \u2013 evaluating progress and challenges","volume":"392","author":"Maddox","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.fhj.2025.100485_bib0039","article-title":"Revolutionising health care with AI: a new era of efficiency, trust, and care excellence","author":"Ronanki","year":"2024","journal-title":"N Engl J Med AI"},{"issue":"10512","key":"10.1016\/j.fhj.2025.100485_bib0040","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0140-6736(24)02151-2","article-title":"Driving down the cost of biologics: lessons from a nationalised health-care system","volume":"404","author":"Russell","year":"2024","journal-title":"Lancet"}],"container-title":["Future Healthcare Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2514664525002644?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2514664525002644?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:25:40Z","timestamp":1778246740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2514664525002644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2514664525002644"],"URL":"https:\/\/doi.org\/10.1016\/j.fhj.2025.100485","relation":{},"ISSN":["2514-6645"],"issn-type":[{"value":"2514-6645","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rheumatology 2050: How our specialty is changing","name":"articletitle","label":"Article Title"},{"value":"Future Healthcare Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fhj.2025.100485","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of Royal College of Physicians.","name":"copyright","label":"Copyright"}],"article-number":"100485"}}